Moderna, Inc. (MRNA) Stock
MRNA Key Statistics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
CEO: Stéphane Bancel. Company website
MRNA — Frequently Asked Questions
What is the MRNA stock price today?
Moderna, Inc. (MRNA) trades at $154.04, down 2.55% on the day, as of Sep 20, 2026 15:01 UTC.
What is Moderna, Inc.'s market cap?
Moderna, Inc. has a market capitalisation of $61.12B, calculated from the live MRNA share price and shares outstanding.
What is the P/E ratio of MRNA?
MRNA has no meaningful price-to-earnings ratio: Moderna, Inc. lost $7.98 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Moderna, Inc. make?
Moderna, Inc. generated revenue of $2.23B over the trailing twelve months, which puts the stock at 27.43 times sales.
What is the 52-week range for MRNA?
MRNA has traded between $22.28 and $176.66 over the past 52 weeks, and the last price is 12.8% below that high.
Is Moderna, Inc. profitable?
No. Moderna, Inc. is loss-making, with a net margin of -141.43% over the trailing twelve months.
What is the analyst price target for MRNA?
Wall Street analysts rate MRNA Hold, with an average price target of $115.70, 24.9% below the current price.
What sector is Moderna, Inc. in?
Moderna, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Moderna, Inc.?
Stéphane Bancel is the chief executive of Moderna, Inc., which employs 4,700 people.
Where can I track MRNA in real time?
QFI Terminal shows MRNA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See MRNA live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open MRNA in Terminal See plans